By Jess Jones Biotech giant GSK has announced a potential breakthrough in the treatment of relapsed or refractory multiple myeloma, a type of blood cancer, with its Blenrep drug. In an interimstudy, a cocktail of drugs was trialled, including one called Blenrep, which GSK found led to a “statistically significant and clinically meaningful improvement”, meaning it helped patients live longer without the cancer getting worse. Patients on the Blenrep combination had a 59 per cent lower risk of their disease getting worse or passing away compared to those on a standard combination. GSK will today …